0001209191-18-027478.txt : 20180502 0001209191-18-027478.hdr.sgml : 20180502 20180502201222 ACCESSION NUMBER: 0001209191-18-027478 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180320 FILED AS OF DATE: 20180502 DATE AS OF CHANGE: 20180502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blackburn Stan CENTRAL INDEX KEY: 0001640577 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 18801417 MAIL ADDRESS: STREET 1: C/O ATYR PHARMA, INC. STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-03-20 0 0001339970 aTYR PHARMA INC LIFE 0001640577 Blackburn Stan 3545 JOHN HOPKINS COURT, SUITE 250 SAN DIEGO CA 92121 0 0 0 1 See Remarks Common Stock 11954 I By the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 2001 Stock Option (right to buy) 0.72 2021-06-02 Common Stock 129 D Stock Option (right to buy) 0.88 2022-09-13 Common Stock 878 D Stock Option (right to buy) 4.06 2023-09-26 Common Stock 2514 D Stock Option (right to buy) 4.06 2024-03-05 Common Stock 1760 D Stock Option (right to buy) 9.15 2025-04-17 Common Stock 3143 D Stock Option (right to buy) 14.00 2025-05-06 Common Stock 4085 D Stock Option (right to buy) 10.24 2025-10-01 Common Stock 9500 D Stock Option (right to buy) 6.14 2026-01-27 Common Stock 4250 D The Reporting Person is a co-trustee of the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 9, 2001. All options reported on this Form 3 were granted prior to February 2016 when the Reporting Person was a consultant, serving as the Company's Acting Chief Financial Officer. On March 20, 2018, the Reporting Person became the Company's Principal Financial and Accounting Officer. This option was fully vested and exercisable at the reporting date. The shares subject to this option vest in 48 equal monthly installments starting on May 17, 2015 and will be fully exercisable on April 17, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer. The shares subject to this option vest in 48 equal monthly installments starting on June 6, 2015 and will be fully exercisable on May 6, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer. The shares subject to this option vest in 48 equal monthly installments starting on November 1, 2015 and will be fully exercisable on October 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer. The shares subject to this option vest in 48 equal monthly installments starting on February 1, 2016 and will be fully exercisable on January 1, 2020. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer. Principal Financial and Accounting Officer Nancy D. Krueger, Attorney-In-Fact 2018-05-02 EX-24 2 attachment1.htm EX-24 DOCUMENT
LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints Nancy Krueger, signing singly,
and with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of aTyr Pharma, Inc. (the "Company"), from time to
time the following U.S. Securities and Exchange Commission ("SEC") forms: (i)
Form ID, including any attached documents, to effect the assignment of codes to
the undersigned to be used in the transmission of information to the SEC using
the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of
Securities, including any attached documents;  (iii) Form 4, Statement of
Changes in Beneficial Ownership of Securities, including any attached documents;
(iv) Form 5, Annual Statement of Beneficial Ownership of Securities in
accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended, and the rules thereunder, including any attached documents; (v)
Schedule 13D and (vi) amendments of each thereof, in accordance with the
Securities Exchange Act of 1934, as amended, and the rules thereunder, including
any attached documents;

	(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5,
Schedule 13D or any amendment(s) thereto, and timely file such form(s) with the
SEC and any securities exchange, national association or similar authority; and

	(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact, acting singly,
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorney-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorney-in-fact.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company.  This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of May 2, 2018.

							/s/ Stan Blackburn
							Stan Blackburn